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 Abbreviation 
 
BBB:   blood-brain barrier 
Carbamoyl-PROXYL: 3-carbamoyl-2,2,5,5-tetramethylpyrrolidine-1-oxyl  
CD:   high cholesterol diet 
EDTA:   ethylenediaminetetraacetic acid 
ELISA:   enzyme-linked immunosorbent assay 
EPR:   electron-paramagnetic resonance 
Gd-DTPA:  gadolinium-diethylenetriamine pentaacetic acid 
HDL:   high-density lipoprotein 
IgG:   immunoglobulin G 
MCAO:   middle cerebral artery occlusion 
MMP:   matrix metalloproteinase 
MRI:   magnetic resonance imaging 
ND:   normal diet 
ROI:   regions of interest 
TIMP:   tissue inhibitor of metalloproteinase 
ZO-1:   zona occludens-1
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Introduction 
Blood-brain barrier (BBB) protects the central nervous system from peripheral 
circulation. BBB impermeability is maintained by brain microvascular endothelial cells through 
their tight junctions and the basal lamina containing extracellular matrix proteins. BBB 
disruption occurs in a variety of neurological disorders including multiple sclerosis, Alzheimer’s 
disease, and AIDS dementia (De Vries et al., 1997; Yong et al., 1998; Hartung and Kieseier, 
2000). Clinical and epidemiological studies showed that high plasma total cholesterol levels are 
associated with an increased risk of Alzheimer’s disease (Notkola et al., 1998; Kuusisto et al., 
1997; Evans et al., 2000; Kivipelto et al., 2006). Recent studies have shown that BBB 
permeability is altered by a high cholesterol diet (CD) in animal models and peripheral 
cholesterol metabolism might affect BBB (Ghribi et al., 2006; Chen et al., 2008; Takechi et al., 
2010). However, the mechanisms by which BBB permeability is increased by dietary 
cholesterol are unclear. 
The conventional methods for investigating BBB permeability in animal models are 
usually invasive or radioactive, such as the detection of serum IgG, exogenous Evans blue dye, 
or [14C]sucrose in the brain. The permeability of BBB can be investigated non-invasively by 
magnetic resonance imaging (MRI), using usually gadolinium-diethylenetriamine pentaacetic 
acid (Gd-DTPA) as a contrast agent (Runge et al., 1985). However, Gd-DTPA-enhanced MRI 
allows visualization of severe injury of BBB. In the present study, a new approach was 
developed for visualization of very small changes in BBB permeability, using 
3-carbamoyl-2,2,5,5-tetramethylpyrrolidine-1-oxyl (carbamoyl-PROXYL) as a MRI contrast 
agent (Anzai et al., 2003). Gd-DTPA and carbamoyl-PROXYL are water-soluble and 
non-permeable for BBB, and both probes are excreted by the kidney. Gd-DTPA possesses a 
relatively high molecular weight (742.79), while carbamoyl–PROXYL possesses a relatively 
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low molecular weight (185.24). Carbamoyl-PROXYL is one of the nitroxide radicals. The 
nitroxide radicals are well-known from electron-paramagnetic resonance (EPR) studies (Rosen 
et al., 1990; Valgimigli et al., 2001; Utsumi et al., 2003). The nitroxides are small molecules, 
sensitive to the reduction status of biological samples and their use in the life science research is 
limited predominantly to tissue redox mapping in vitro and in vivo, using EPR imaging (EPRI) 
or MRI (Utsumi et al., 2003; Matsumoto et al., 2006; Hyodo et al., 2006; Soule et al., 2007; 
Zhelev et al., 2009; Zhelev et al., 2010). The paramagnetic nitroxide radical could be reduced to 
diamagnetic hydroxylamine with a loss of EPR signal or 1H-MRI relaxivity and thus to serve as 
a reduction sensor. However, the diamagnetic hydroxylamine could be re-converted via 
oxygenation to paramagnetic nitroxide radical with an appearance of EPR signal or 1H-MRI 
relaxivity and thus to serve as an oxidation sensor. The rate-constants of both processes could be 
used for the evaluation of tissue redox status. 
BBB permeability enhancement after ischemia is accompanied with up-regulation of 
matrix metalloproteinases (MMPs) (Mun-Bryce and Rosenberg, 1998a). MMP-2 (72-kDa type 
IV collagenase or gelatinase A) and MMP-9 (92-kDa type IV collagenase or gelatinase B) 
belong to the subclass of gelatinase. They degrade components of extracellular matrix in the 
basal lamina, including collagen, laminin, and zona occludens-1 (ZO-1) in the endothelial tight 
junctions (Romanic and Madri, 1994; Rosenberg et al., 2001). It has been reported that MMP-2 
and MMP-9 are involved in BBB disruptions (Mun-Bryce and Rosenberg, 1998b; Rosenberg et 
al., 1998; Gasche et al., 1999). The knockout mice for the MMP-9 gene demonstrate a reduced 
permeability of BBB after ischemia in comparison with wild-type mice (Asahi et al., 2001). 
Treatment with MMP inhibitor reduces tissue damages (Mun-Bryce and Rosenberg, 1998b; 
Romanic et al., 1998). In this context, the working hypothesis is that MMP-2 and/or MMP-9 
could be involved in the enhancement of BBB permeability of mice on a CD. 
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To assess the effects of anti-lipidemic drugs on the BBB disruptions and the renal 
dysfunction induced by CD, cholestyramine and ezetimibe were used in this study. 
Cholestyramine is an ion-exchanged polymer and a bile acid sequestrant. Bile acids are 
synthesized in the liver from cholesterol and secreted to the intestine through the gallbladder. 
Bile acids are re-absorbed in the intestine and transported back to the liver, and are thus 
conserved through the enterohepatic circulation. Cholestyramine binds bile acids in the intestine 
and prevents their re-absorption (Thompson, 1971). The low level of bile acids in the portal vein 
and liver induces the synthesis of bile acids in the liver and the transport of cholesterol from the 
blood. Thus, plasma cholesterol decreases. Ezetimibe is an inhibitor of Niemann-Pick C1-Like 1 
(NPC1L1) that is critical for cholesterol uptake in enterocytes (Garcia-Calvo et al, 2005). It 
suppresses dietary and biliary cholesterol absorption in the intestine and decreases the plasma 
cholesterol level. 
The purpose of this study was to clarify whether Gd-DTPA and carbamoyl-PROXYL 
are appropriate for non-invasive MRI of very small disruptions of BBB and the renal 
dysfunction induced by dietary cholesterol in mice as well as to assess the effect of 
anti-lipidemic drugs such as cholestyramine and ezetimibe on the BBB disruptions and the renal 
dysfunction. This study also aimed to investigate the mechanisms of the BBB disruptions and 
the renal dysfunction by dietary cholesterol. 
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Materials and methods 
Animals 
The care, maintenance, and experiments with animals were in accordance to the 
“Principles of Laboratory Animal Care” (NIH publication number 85-23, revised 1985) and the 
Guidelines of the Animal Investigation Committee of Chiba University (Chiba, Japan) and 
National Institute of Radiological Sciences (Chiba, Japan). This study protocol was approved by 
the Animal Care and Use Committee of Chiba University. 
Male C57Bl/6 mice were purchased from Charles River Laboratories Japan Inc. 
(Kanagawa, Japan). Mice were subjected to a normal diet (ND) (MF; Oriental Yeast Co., Tokyo, 
Japan) or a CD (ATT6492210; 1.25% [wt/wt] cholesterol, Oriental Yeast Co.) starting at 5 
weeks of age. Ezetimibe (0.01%) and cholestyramine (3%) was administered to mice subjected 
to CD with food admixture. Throughout the experiments, the mice were kept in stainless steel 
cages with food and water available ad libitum, and maintained on a 12-h light-dark cycle. 
 
In vivo MRI measurements 
The MRI measurements were performed on 7.0 Tesla horizontal magnet (Kobelco and 
Jastec, Kobe, Japan) interfaced to a Bruker Avance-I console (Bruker BioSpin, Rheinstetten, 
Germany) and controlled with ParaVision 4.0.1 (Bruker BioSpin). 
Mice were anesthetized by isoflurane (1.2%, Abbott Japan, Tokyo, Japan) and placed in 
a body holder (Rapid Biomedical, Rimpar, Germany), stomach side down and fixed head. 
Polyethylene catheter (PE-10, Becton-Dickinson, NJ, USA) was placed in the tail vein for probe 
administration. The mouse was then placed in the 1H-volume radio-frequency (RF) resonator 
(Bruker BioSpin) with surface RF receiver (Rapid Biomedical). Rectal temperature of the 
mouse was maintained at 37.0 ± 0.5oC using an automatic controlled electric heater and 
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monitored using an optical temperature probe (FOT-M and FTI-10, FISO Technology, Quebec, 
Canada). A respiration sensor (SA Instruments, Edison, NY, USA) was placed on the chest of 
the mouse for monitoring. 
Before probe administration, five control images of the mouse brain were acquired with 
the following parameters: T1-weighted incoherent gradient-echo sequence (fast low-angle shot); 
repetition time = 75 ms; echo time = 3.2 ms; flip angle = 45 degrees; field of view = 19.2 x 19.2 
mm; number of averages = 4; scan time = 19.2 seconds; matrix = 64 x 64; slice thickness = 1.0 
mm; number of slices = 4. We selected the coronal slice orientations with a 300 x 300 x 1000 
µm3 nominal voxel resolution. Ninety-six seconds after starting the MRI scan (5 images 
acquired as pre-administration data), 100 µL of Gd-DTPA (Meglumine Gadopentetate, Bayer 
HealthCare, Osaka, Japan) (final concentration - 0.125 mmol/kg; Gd-DTPA was dissolved in 
dimethylsulfoxide) or 100 µL of nitroxide probe (carbamoyl-PROXYL, Sigma-Aldrich, St. 
Louis, MO, USA) (final concentration - 0.4 mmol/kg; carbamoyl-PROXYL was dissolved in 
dimethylsulfoxide) was injected via the tail vein. T1-weighted images were acquired 
continuously within ~20 min. Mice injected with dimethylsulfoxide only (in the same volume – 
100 µL) served as controls. The MRI data were analyzed using the ImageJ (National Institute of 
Health, Bethesda, MD, USA) software. The regions of interest (ROI) were defined as the entire 
brain (ROI-1), the soft tissues surrounding the brain (ROI-2) (Figure 1), and the kidney (ROI-3). 
The MRI signal intensity after probe injection was normalized to the average MRI signal 
intensity before injection (first 5 frames) using the ImageJ software. 
 
Determination of plasma cholesterol levels 
Blood samples for cholesterol and MMP determination were taken from the tail vein in 
a heparinized microhematocrit tube. The blood samples were centrifuged at 12,000 g for 5 min  
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(brain)
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(surrounding tissues)
Brain imaging
Figure 1.  Definition of the regions of interest (ROI). The ROI-1 and 
-2 were defined as the brain and the soft tissues surrounding the brain, 
respectively. 
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at room temperature to obtain plasma. Plasma was stored at -80oC until cholesterol and MMP 
determination. The total cholesterol levels were determined by a modification of the cholesterol 
oxidase method with the use of kit reagents (Wako Pure Chemical Industries, Osaka, Japan). 
The high-density lipoprotein (HDL) cholesterol levels were measured by the cholesterol oxidase 
assay of the supernatant from the precipitate of non-HDL lipoproteins with phosphotungstic 
acid and magnesium chloride using the kit reagents (Wako Pure Chemical Industries). The 
non-HDL cholesterol levels were calculated as HDL cholesterol levels subtracted from total 
cholesterol levels. 
 
Determination of plasma MMP-2 and MMP-9 levels  
Enzyme-linked immunosorbent assay (ELISA) was used to determine plasma total 
MMP-2 and total MMP-9 levels according to the manufacturer’s instructions. The MMP-2 
ELISA kit (Human/Mouse/Rat MMP-2 [total], Quantikine; R&D Systems, Inc., Minneapolis, 
MN, USA) detects pro-, active, and tissue inhibitor of metalloproteinase (TIMP)-complexed 
MMP-2. The MMP-9 ELISA kit (Mouse MMP-9 [total], Quantikine; R&D Systems, Inc.) 
detects pro-, active, and TIMP-complexed MMP-9. Plasma obtained from mice at 15 weeks of 
age was analyzed. 
 
White blood cell differential analysis 
Blood samples for white blood cell differential analysis were taken from the tail vein in 
an EDTA-treated microhematocrit tube. Blood samples for time course analysis of the change of 
white blood cells were taken from the vena cava in the anesthetized condition with 
intraperitoneal injection of sodium pentobarbital (40 mg/kg, Dainippon Sumitomo Pharma Co., 
Osaka, Japan), and the samples were transferred to an EDTA-treated tube. White blood cell 
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differential analyses were performed by an automated hematology analyzer (Advia 120, Bayer 
Diagnostics, Tarrytown, NY, USA). 
 
Statistical analysis 
The results are expressed as mean ± standard error (SE). Statistical analyses were 
conducted with SAS System Release 8.2 (SAS Institute Inc., Cary, NC, USA). Comparisons 
between ND and CD groups were performed with Student’s t test. Comparisons of drug-treated 
groups with CD group were performed with Dunnett’s test. Pearson correlation analysis was 
performed between plasma total MMP-9 levels or proportion of neutrophils and plasma total 
cholesterol levels. A value of p<0.05 was considered significant. 
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Results 
Changes of plasma cholesterol levels and body weight in ND and CD mice 
Male C57Bl/6 mice were subjected to ND (control group) or CD starting at 5 weeks of 
age. After 15 weeks of age, the mice were used for MRI evaluation of vasculature permeability 
and renal function, MMP determination, and white blood cell differential analysis. CD mice 
weighed less than ND mice (21.0 ± 1.2 g vs. 39.0 ± 0.7 g at 36 weeks of age). The results in 
Figure 2 demonstrate that total plasma cholesterol (Figure 2A) and non-HDL cholesterol (Figure 
2C) increased significantly in CD mice, while HDL cholesterol decreased significantly in the 
same mice (Figure 2B) in comparison with ND mice. 
 
Permeability of BBB in ND and CD mice 
Figure 3A shows the time course of MRI signal enhancement in ROI-1 before and after 
Gd-DTPA administration in ND mice or CD mice. No MRI signal enhancement induced by 
Gd-DTPA in ROI-1 was detected in either group (Figure 3A; ND - open circle; CD - closed 
circle). However, different results were obtained using a nitroxide probe, carbamoyl-PROXYL, 
which is practically non-permeable for BBB (Anzai et al., 2003). The signal enhancement 
induced by carbamoyl-PROXYL in ROI-1 of ND mice was very weak and disappeared 
completely within 10 min after administration (Figure 3B – open circle). On the other hand, in 
CD mice (ROI-1), the signal enhancement induced by carbamoyl-PROXYL increased rapidly 
and was maintained for at least 14 min after administration (Figure 3B – closed circle). These 
data show that small disruptions, which can be detected by carbamoyl-PROXYL (but not by 
Gd-DTPA), occurred in BBB in CD mice. 
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Figure 2.  Plasma cholesterol levels in mice subjected to a normal or a high cholesterol diet. 
Mice were subjected to a normal or a high cholesterol diet starting at 5 weeks of age. A, Plasma 
total cholesterol. B, HDL cholesterol. C, non-HDL cholesterol. Open circle, normal diet; closed 
circle, high cholesterol diet. Results are means ± SE, n=6-7/group. Plasma total cholesterol, HDL 
cholesterol, and non-HDL cholesterol levels at all time points after week 15 were significantly 
different between normal and high cholesterol diet groups. Mice were used after 15 weeks of age 
for MRI evaluation, MMP determination, and white blood cell differential analysis. 
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Figure 3.  MRI signal dynamics induced by Gd-DTPA and carbamoyl-PROXYL in the 
brain (ROI-1) after intravenous administration. Arrows indicate the time of administration 
of Gd-DTPA (A) or carbamoyl-PROXYL (B). Open circle, normal diet; closed circle, high 
cholesterol diet. Mean data from 4 mice per group are presented in the figure. In the 
images: the white color is the extraction of the MRI signal between the slide, obtained ~5 
min after injection of Gd-DTPA or carbamoyl-PROXYL and the averaged baseline signal 
(before injection). 
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Permeability of blood vasculature in the soft tissues surrounding the brain of ND and CD 
mice 
In Figure 4A, the open circles represent the time course of MRI signal dynamics in 
ROI-2 (Figure 1) before and after Gd-DTPA administration in ND mice. The MRI signal decay 
after Gd-DTPA administration followed a typical kinetic pattern with a half-life ~12 min 
(Bousquet et al., 1988). On the other hand, the MRI signal enhancement induced by Gd-DTPA 
in the same ROI-2 of CD mice strongly increased and was maintained within at least 14 min 
after Gd-DTPA administration (Figure 4A – closed circle). Similar results were also obtained 
using carbamoyl-PROXYL. The half-life of MRI signal decay after carbamoyl-PROXYL 
administration in ROI-2 of ND mice was ~7 min (Figure 4B – open circle). In CD mice, the 
half-life of MRI signal decay after carbamoyl-PROXYL administration was over 15 min (Figure 
4B – closed circle). 
 
Effects of ezetimibe and cholestyramine on plasma cholesterol levels in CD mice 
Ezetimibe (0.01%) and cholestyramine (3%) was administered to mice subjected to 
cholesterol diet with food admixture. Ezetimibe and cholestyramine decreased plasma total 
cholesterol (Figure 5A) and non-HDL cholesterol levels (Figure 5C) and increased HDL 
cholesterol levels (Figure 5B). 
 
Effects of ezetimibe and cholestyramine on the permeability of BBB in CD mice 
The amplitude of MRI signal enhancement in cholestyramine and ezetimibe-treated CD 
mice was the same as that in ND mice in ROI-1 at early exposure time (–5 min) after injection 
of carbamoyl-PROXYL (Figure 6). However, this protective effect of cholestyramine and 
ezetimibe on CD mice disappeared within 14 min. The data suggest that both drugs decreased  
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Figure 4.  MRI signal dynamics of Gd-DTPA and carbamoyl-PROXYL in 
the soft tissues surrounding the brain (ROI-2) after intravenous 
administration. Arrows indicate the time of administration of Gd-DTPA (A) 
or carbamoyl-PROXYL (B). Open circle, normal diet; closed circle, high 
cholesterol diet. Mean data from 4 mice per group are presented in the 
figure. 
A 
B 
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Figure 5.  Plasma cholesterol levels in ezetimibe- or cholestyramine-treated mice. 
A, Plasma total cholesterol. B, HDL cholesterol. C, non-HDL cholesterol. Closed 
circle, cholesterol control; closed red square, ezetimibe; closed blue triangle, 
cholestyramine; open circle, normal diet. Results are means ± SE., n=6-7/group. 
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Figure 6.  MRI signal dynamics induced by carbamoyl-PROXYL in the brain (ROI-1) 
after intravenous administration. Arrows indicate the time of administration of 
carbamoyl-PROXYL. Closed circle, cholesterol control; closed red square, ezetimibe; 
closed blue triangle, cholestyramine; open circle, normal diet. Mean data from 4 mice 
per group are presented in the figure. 
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the rate of penetration of carbamoyl-PROXYL in the brain tissue without completely preventing 
the effect of CD on BBB permeability. 
 
Effects of ezetimibe and cholestyramine on the permeability of blood vasculature in the soft 
tissues surrounding the brain in CD mice 
The amplitude of MRI signal enhancement in cholestyramine and ezetimibe-treated 
mice was the same as that in ND mice in ROI-2 (Figure 7). Both drugs abolished completely the 
effect of CD on MRI signal enhancement by carbamoyl-PROXYL in ROI-2. 
 
Renal function in ND and CD mice 
Figure 8 shows the time course of MRI signal enhancement in ROI-3 before and after 
carbamoyl-PROXYL administration in ND mice and CD mice. In ND mice, the MRI signal 
intensity increased after injection of carbamoyl-PROXYL, reached a maximum (renal filtration 
peak) and then decreased (excretion part) to the baseline level within 14 min (Figure 8B – blue 
curve). The half-life of MRI signal decay was ~4 min. In CD mice, the MRI signal intensity 
after injection of carbamoyl-PROXYL was the same as the baseline – without renal filtration 
peak and excretion part (Figure 8B – red curve). The color images in Figure 8A show that MRI 
signal enhancement was not detected in the kidney of CD mice. 
 
Effects of ezetimibe and cholestyramine on the renal function in CD mice 
The data in Figures 9 and 10 show the effect of anti-lipidemic drugs on renal function, 
using carbamoyl-PROXYL-enhanced MRI. In the case of cholestyramine-treated mice, the MRI 
signal intensity in ROI-3 followed the same dynamics as ND mice – increase during first two 
minutes after injection of nitroxide, reaching a maximum and decrease to the baseline level  
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Figure 7.  MRI signal dynamics induced by carbamoyl-PROXYL in the soft tissues 
surrounding the brain (ROI-2) after intravenous administration. Arrows indicate the time of 
administration of carbamoyl-PROXYL. Closed circle, cholesterol control; closed red 
square, ezetimibe; closed blue triangle, cholestyramine; open circle, normal diet. Mean 
data from 4 mice per group are presented in the figure. 
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Carbamoyl-PROXYL 
Figure 8.  MRI signal dynamics induced by carbamoyl-PROXYL in the kidney 
(ROI-3) after intravenous administration. (A) Black & white images: T1-weighted MR 
images of the kidney before the injection of carbamoyl-PROXYL. Color images: 
Extracted MRI signal intensity normalized to the averaged baseline level (before 
injection of carbamoyl-PROXYL). (B) Kinetic curves of normalized MRI signal intensity 
before and after injection of carbamoyl-PROXYL in mice subjected to normal diet (blue 
curve) and cholesterol diet (red curve). Results are means ± SE., n=5/group. 
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Carbamoyl-PROXYL 
Figure 9.  Effect of cholestyramine on carbamoyl-PROXYL-enhanced MRI of the 
kidney (ROI-3) in mice subjected to cholesterol diet. . (A) Black & white images: 
T1-weighted MR images of the kidney before the injection of carbamoyl-PROXYL. Color 
images: Extracted MRI signal intensity normalized to the averaged baseline level (before 
injection of carbamoyl-PROXYL). (B) Kinetic curves of normalized MRI signal intensity 
before and after injection of carbamoyl-PROXYL in mice subjected to cholesterol diet. Red 
curve, cholesterol control; green curve, cholestyramine. Results are means ± SE., 
n=5/group. 
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Carbamoyl-PROXYL 
Figure 10.  Effect of ezetimibe on carbamoyl-PROXYL-enhanced MRI of the kidney 
(ROI-3) in mice subjected to cholesterol diet. . (A) Black & white images: T1-weighted 
MR images of the kidney before the injection of carbamoyl-PROXYL. Color images: 
Extracted MRI signal intensity normalized to the averaged baseline level (before injection 
of carbamoyl-PROXYL). (B) Kinetic curves of normalized MRI signal intensity before and 
after injection of carbamoyl-PROXYL in mice subjected to cholesterol diet. Red curve, 
cholesterol control; green curve, ezetimibe. Results are means ± SE., n=5/group. 
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within 14 min (Figure 9B – green curve). The half-life of MRI signal decay was ~4 min 30 sec. 
Cholestyramine partially prevents the negative effects of CD on renal function. In the case of 
ezetimibe-treated mice (Figure 10B – green curve), the MRI signal dynamics in the kidney after 
injection of nitroxide followed the same profile, but not well defined as in the case of 
cholestyramine (Figure 9B – green curve). Sometimes the signal was recorded in one kidney, 
but not in the other (Figure 10A). Ezetimibe manifested a slight positive effect on 
hypercholesterolemia-mediated renal dysfunction. 
 
The dynamics of Gd-DTPA-enhanced MRI signal in ROI-3 of ND and CD mice 
In parallel, the dynamics of Gd-DTPA-enhanced MRI signal in the ROI-3 of ND and 
CD mice were also investigated (Figure 11A1 and A2). The kinetic curves had different profiles 
in comparison with carbamoyl-PROXYL. However, there was also a difference between ND 
mice and CD mice. In ND mice, the kinetic curve was characterized with three major parts: (i) 
baseline (before contrast administration); (ii) renal filtration peak; and (iii) excretion part 
(Figure 11A1). In CD mice, the renal filtration peak was not well-defined (Figure 11A2). The 
kinetics of Gd-DTPA-enhanced MRI signal in the kidney of ND and CD mice was similar to 
that of humans, subjected to MR urography. Figure 11B represents one typical clinical case. In 
human, the ROI was placed first around and in the aorta, then around the selected kidney and 
within the renal parenchyma, excluding the renal pelvis from the analysis. Figure 11B1 
represents the typical enhancement curves in a normal kidney with very well-defined arterial 
and glomerular filtration peaks. Figure 11B2 represents typical enhancement curves in a 
damaged kidney. The arterial peak is missing, glomerular filtration peak is poorly defined. 
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Figure 11.  (A) Kinetic curves of normalized MRI signal intensity in the kidney (ROI-3) 
before and after injection of Gd-DTPA in mice subjected to normal diet (blue curve) or 
cholesterol diet (red curve). Mean data from 4 mice per group are presented in the figure. (B) 
Typical kinetic curves of Gd-DTPA-enhanced MRI in the kidney (ROI-3) of healthy human 
(B1) and human with renal pathology (B2). CHOP-fMRU software was used for the data 
processing of the postcontrast T1 VIBE Dynamic sequence in coronal plane during the 
excretory MR urography. 
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CD increases the plasma MMP-9 levels 
To investigate the potential mechanisms for increased permeability of BBB in CD mice, 
plasma levels of MMP-2 and MMP-9 were analyzed. BBB permeability enhancement after 
ischemia is known to be accompanied with up-regulation of MMPs. In this study, it seemed 
reasonable to assume that MMP-2 and/or MMP-9 could be involved in the enhancement of 
BBB permeability of CD mice. Although there was no significant difference in plasma total 
MMP-2 levels between ND and CD mice (Figure 12A), plasma total MMP-9 levels in CD mice 
were significantly higher than those in ND mice (Figure 12B). The treatment of cholestyramine 
and ezetimibe significantly decreased the plasma total MMP-9 levels increased by CD (Figure 
12B). Moreover, significant correlation between the plasma total MMP-9 levels and plasma 
total cholesterol levels was observed (Figure 13). 
 
CD increases the proportion of neutrophils in the blood 
White blood cell differential analysis was conducted to determine whether the increased 
plasma MMP-9 levels observed in CD mice were due to changes in composition with white 
blood cells. It is well known that MMP-9 is produced predominantly by neutrophils and 
monocytes in the blood (Opdenakker et al, 2001). CD significantly increased the proportion of 
neutrophils, decreased the proportion of lymphocytes and had no effects on monocytes (Figure 
14), eosinophils or basophils (data not shown). The treatment of cholestyramine and ezetimibe 
significantly decreased the proportion of neutrophils increased by CD (Figure 15A). Moreover, 
significant correlation between the proportion of neutrophils and plasma total cholesterol levels 
was observed (Figure 16). 
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Figure 12.  Plasma total matrix metalloproteinases (MMP) levels in mice subjected to 
cholesterol diet treated with ezetimibe or cholestyramine. Plasma total MMP-2 (A) and 
MMP-9 (B). Results are means ± SE. ***p<0.001 vs. normal diet (Student’s t test); 
#p<0.05 vs. cholesterol control (Dunnett’s test); n=6-7/group. 
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Figure 13.  Correlation between plasma total MMP-9 and total cholesterol levels. 
Each dot represents the individual plasma total MMP-9 levels against plasma total 
cholesterol levels. Closed circle, cholesterol control; closed square, ezetimibe; closed 
triangle, cholestyramine; open circle, normal diet. Pearson correlation analysis was 
performed between the plasma total MMP-9 levels and plasma total cholesterol levels. 
r=0.6117 
P<0.001 
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Figure 14.  The changes of white blood cells with treatment period of high cholesterol diet in mice. 
White blood cell count (A), and proportion of neutrophils (B), lymphocytes (C), monocytes (D). 
Open circle, normal diet; closed circle, cholesterol diet. Results are means ± SE. *p<0.05, **p<0.01, 
***p<0.001, Student’s t test; n=3-5/group. 
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Figure 15.  White blood cell differential analysis in mice subjected to cholesterol diet treated 
with ezetimibe or cholestyramine. Proportion of neutrophils (A), lymphocytes (B), and 
monocytes (C). Results are means ± SE. **p<0.01, ***p<0.001 vs normal diet (Student’s t 
test); #p<0.05, ##p<0.01 vs. cholesterol control (Dunnett’s test), n=6-7/group. 
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Figure 16.  Correlation between the proportion of neutrophils and plasma total 
cholesterol levels. Each dot represents the individual proportion of neutrophils 
against plasma total cholesterol levels. Closed circle, cholesterol control; closed 
square, ezetimibe; closed triangle, cholestyramine; open circle, normal diet. Pearson 
correlation analysis was performed between the proportion of neutrophils and 
plasma total cholesterol levels. 
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 5 10 15
Plasma total cholesterol (mmol/L)
Pr
op
ot
io
n 
of
 n
eu
tr
op
hi
l
Cholesterol control
Ezetimibe
Cholestyramine
Normal diet
All
線形  (All)
r=0.6256 
P<0.001
r .6256 
P<0.001 
- 29- 
Discussion 
Recent studies have shown that BBB permeability is altered by CD in animal models 
(Ghribi et al., 2006; Chen et al., 2008; Takechi et al., 2010). In this study, mice subjected to CD 
were selected as the animal model that demonstarates inceased BBB permeability. CD mice 
significantly increased total plasma cholesterol and non-HDL cholesterol levels and decreased 
HDL cholesterol levels with comparison to ND mice (Figure 2). 
Both MRI contrast probes used in this study are generally non-permeable for BBB. 
Gd-DTPA is a larger molecule (molecular weight, 742.79) than carbamoyl–PROXYL 
(molecular weight, 185.24). In the brain of ND and CD mice, MRI signal enhancement was not 
detected by Gd-DTPA (Figure 3A). However, after administration of carbamoyl-PROXYL, the 
MRI signal intensity in the brain of CD mice was significantly higher than in ND mice (Figure 
3B). It can be assumed that CD induces small disruptions in BBB, which can be detected using 
“carbamoyl-PROXYL-enhanced MRI”, but not by Gd-DTPA. The permeability of BBB for 
carbamoyl-PROXYL increased in CD mice. Small disruptions in the BBB are trigger signal for 
early brain injury. Such abnormality is usually detectable using indirect cerebrospinal fluid 
biomarkers (Pancotto et al., 2010). 
On the other hand, the MRI signal of the soft tissues surrounding the brain (ROI-2) 
strongly increased after administration of Gd-DTPA in CD mice, and the signal did not decrease 
within ~14 min scan time (Figure 4A). In ND mice, the half-life of MRI signal decay after 
administration of Gd-DTPA was ~15 min. These data suggest that CD increases the permeability 
of blood vasculature in the soft tissues surrounding the brain and that CD decreases the 
excretion of Gd-DTPA from the kidney. Figure 11A2 shows the renal filtration peak in CD mice 
was not well-defined, indicating renal dysfunction in CD mice. In ROI-2 (the soft tissues 
surrounding the brain) of ND mice, carbamoyl–PROXYL-enhanced MRI signal followed a 
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typical kinetic (Figure 4B). However, the half-life of MRI signal decay in CD mice was longer 
than that in ND mice (Figure 4B). These data suggest that CD decreases the excretion of 
carbamoyl-PROXYL from the kidney. In Figure 8, the carbamoyl-PROXYL-enhanced MRI 
signal was not detected in ROI-3 of CD mice, indicating that CD leads to impaired or reduced 
renal filtration, which prevents the penetration of carbamoyl-PROXYL in the kidneys. 
Carbamoyl-PROXYL is one of the nitroxide radicals. Nitroxide radicals are reported to be 
red/ox sensitive probes because the conversion from a radical to hydroxylamine form is 
accompanied by the loss of MRI signal enhancement (Zhelev et al, 2009). Therefore, these data 
also show a possibility that CD decreases the reduction potential in the soft tissues surrounding 
the brain. 
To assess the effect of anti-lipidemic drugs on the BBB disruptions and the renal 
dysfunction induced by CD, ezetimibe (0.01%) and cholestyramine (3%) was administered to 
CD mice with food admixture. Ezetimibe and cholestyramine decreased plasma total cholesterol 
and non-HDL cholesterol levels and increased HDL cholesterol levels (Figure 5). Ezetimibe and 
cholestyramine decreased the rate of penetration of carbamoyl-PROXYL at early exposure time 
(–5 min) after injection in the brain (Figure 6), indicating that both anti-lipidemic drugs at least 
partially abolished small disruptions of BBB induced by CD. However, the amplitude of MRI 
signal enhancement in cholestyramine and ezetimibe-treated mice was increased in ROI-1 at 
late exposure time (5 min–) after injection of carbamoyl-PROXYL (Figure 6), indicating two 
possibilities: (i) BBB impermeability is not completely recovered by cholestyramine and 
ezetimibe; and (ii) reduction potential in the brain of cholestyramine and ezetimibe-treated mice 
is decreased compared to ND mice. BBB impermeability is maintained by endothelial cells 
through their tight junctions and the basal lamina as well as astrocytes (Palmer et al., 2010). 
Complete recovery of BBB impermeability might be difficult if CD could damage astrocytes in 
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addition to endothelial cells and the basal lamina because astrocytes are one of the glial cells 
and regulate the external chemical environment of neurons. 
In the kidney (ROI-3) of CD mice, the MRI signal intensity after injection of 
carbamoyl-PROXYL was the same as the baseline – without renal filtration peak and excretion 
part (Figure 8B – red curve). There are two possible reasons for this observation: (i) CD leads to 
impaired or reduced renal filtration, which prevents the penetration of carbamoyl-PROXYL in 
the kidney; and (ii) CD leads to a significant increase in reduction potential of the kidney, which 
is accompanied with rapid conversion of carbamoyl-PROXYL from radical to hydroxylamine 
form and loss of MRI signal. The second assumption is unlikely. The previously published data 
show that hypercholesterolemia induces oxidative stress and inflammatory response, which are 
involved in renal injury in mammalians (Eddy, 1998; Montilla et al., 2006; Okamura et al., 
2009). All these events are accompanied by an increased level of reactive oxygen species and 
decreased level of endogenous reducing equivalents in the kidney. Therefore, in CD mice, the 
rate of oxidation of carbamoyl-PROXYL should be considerably higher than the rate of its 
reduction and loss of T1 relaxivity should not be observed. The absence of nitroxide-enhanced 
MRI signal in CD mice seems not to relate to a high redox activity of renal tissue and seems to 
relate to impaired or reduced renal filtration. Whatever the cause of the kidney dysfunction, the 
drastic difference between both kinetic curves in Figure 8 shows that carbamoyl-PROXYL is a 
suitable contrast agent for MRI of this anomaly induced by CD. 
As a result of assessment of the effect of anti-lipidemic drugs on renal dysfunction 
using carbamoyl-PROXYL-enhanced MRI, cholestyramine and ezetimibe at least partially 
abolished the effect of CD in the kidney (Figures 9 and 10), indicating that both drugs abolished 
partially renal dysfunction induced by CD. 
It has been reported that MMP-2 and MMP-9 are involved in BBB disruptions 
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(Mun-Bryce and Rosenberg, 1998b; Rosenberg et al., 1998; Gasche et al., 1999). Although there 
was no significant difference in plasma total MMP-2 levels between ND and CD mice (Figure 
12A), plasma total MMP-9 levels in CD mice were significantly higher than those in ND mice 
(Figure 12B). The treatment of cholestyramine and ezetimibe significantly decreased the plasma 
total MMP-9 levels increased by CD (Figure 12B). Moreover, significant correlation between 
the plasma total MMP-9 levels and plasma total cholesterol levels was observed (Figure 13). It 
has been reported that BBB disruptions occur in a biphasic pattern following middle cerebral 
artery occlusion (MCAO) in rats (Kuroiwa et al, 1985; Belayev et al, 1996). MMP-2 is 
associated with early BBB disruption (1h after MCAO) (Heo et al., 1999), and MMP-9 is 
maximally elevated at the time of secondary disruption (12 to 24h after MCAO) (Rosenberg et 
al, 1996). This study demonstrates that only plasma MMP-9 levels, not MMP-2 levels, 
increased in CD mice (Figure 12B). CD may lead to chronic changes in this animal model, 
accompanied with an enhancement of plasma MMP-9 levels. In humans, it is reported that 
patients with combined dyslipidemia had two times higher plasma MMP-2 and ten times higher 
plasma MMP-9 levels (Derosa et al., 2009), and that therapy with statins not only improved 
lipid profiles but also decreased MMP-9 (Koh et al, 2004; Qu et al, 2008). 
Since it is well known that MMP-9 is produced predominantly by neutrophils and 
monocytes in the blood (Opdenakker et al, 2001), white blood cell differential analysis was 
conducted to determine whether the increased plasma MMP-9 levels observed in CD mice were 
due to changes in composition with white blood cells. CD increased the proportion of 
neutrophils, decreased the proportion of lymphocytes and had no effects on monocytes (Figure 
14), eosinophils or basophils (data not shown). The treatment of cholestyramine and ezetimibe 
significantly decreased the proportion of neutrophils increased by CD (Figure 15A). Moreover, 
significant correlation between the proportion of neutrophils and plasma total cholesterol levels 
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was observed (Figure 16). It seems that MMP-9 in CD mice is produced predominantly by 
neutrophils. 
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Summary 
The purpose of this study was to clarify whether Gd-DTPA and carbamoyl-PROXYL 
are appropriate for non-invasive MRI of very small disruptions of BBB and the renal 
dysfunction induced by dietary cholesterol in mice as well as to assess the effect of 
anti-lipidemic drugs such as cholestyramine and ezetimibe on the BBB disruptions and the renal 
dysfunction. This study also aimed to investigate the mechanisms of the BBB disruptions and 
the renal dysfunction by dietary cholesterol. 
Plasma total cholesterol and non-HDL cholesterol increased significantly in CD mice, 
while HDL cholesterol decreased significantly in the same mice in comparison with ND mice. 
In ROI-1 (the brain) of ND and CD mice, MRI signal enhancement was not detected by 
Gd-DTPA. In ROI-1 of ND mice, carbamoyl–PROXYL-induced MRI signal enhancement was 
negligible, while in CD mice it was significant (τ1/2>15 min). These data indicate that small 
disruptions, which can be detected by carbamoyl-PROXYL (but not by Gd-DTPA), occurred in 
BBB in CD mice. 
In ROI-2 (the soft tissues surrounding the brain) of ND mice, carbamoyl–PROXYL- or 
Gd-DTPA-enhanced MRI signal followed a typical kinetic with a half-life of signal decay (τ1/2) 
~8 or ~15 min, respectively. In CD mice, MRI-signal increased continuously without decay. 
These data show possibilities, (i) CD increases the permeability of blood vasculature in the soft 
tissues surrounding the brain, (ii) CD decreases the excretion of the probe from kidney, and (iii) 
CD decreases the reduction potential in the soft tissues surrounding the brain. 
Cholestyramine (3%) and ezetimibe (0.01%) decreased plasma total cholesterol and 
non-HDL cholesterol levels and increased non-HDL cholesterol levels in CD mice. The 
amplitude of MRI signal enhancement in cholestyramine and ezetimibe-treated CD mice was 
the same as that in ND mice in ROI-1 at early exposure time (–5 min) after injection of 
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carbamoyl-PROXYL. However, this protective effect of cholestyramine and ezetimibe on CD 
mice disappeared within 14 min. The data suggest that both drugs decreased the rate of 
penetration of carbamoyl-PROXYL in the brain tissue without completely preventing the effect 
of cholesterol on BBB permeability. In contrast, both drugs abolished completely the effect of 
CD on MRI signal enhancement by carbamoyl-PROXYL in ROI-2. 
In ROI-3 (the kidney) of ND mice, the MRI signal intensity increased after injection of 
carbamoyl-PROXYL, reached a maximum (very well-defined renal filtration peak) and 
decreased to the baseline level within 14 min. On the other hand, the 
carbamoyl-PROXYL-enhanced MRI signal was not detected in ROI-3 of CD mice, indicating 
that CD leads to impaired or reduced renal filtration, which prevents the penetration of 
carbamoyl-PROXYL in the kidney. Cholestyramine and ezetimibe at least partially abolished 
the effect of CD on carbamoyl-PROXYL-enhanced MRI in the kidney. In parallel, the dynamics 
of Gd-DTPA-enhanced MRI signal in the kidney of ND and CD mice were also investigated. In 
ND mice, the kinetic curve was characterized with three major parts: (i) baseline (before 
contrast administration); (ii) renal filtration peak, and (iii) excretion part. In CD mice, the renal 
filtration peak was not well-defined. 
BBB permeability enhancement after ischemia is known to be accompanied with 
up-regulation of MMPs. In this study, it seemed reasonable to assume that MMP-2 and/or 
MMP-9 could be involved in the enhancement of BBB permeability of mice on a CD. Although 
there was no significant difference in plasma total MMP-2 levels between ND and CD mice, 
plasma total MMP-9 levels in CD mice were significantly higher than those in ND mice. The 
treatment of cholestyramine and ezetimibe significantly decreased the plasma total MMP-9 
levels increased by CD. Moreover, significant correlation between the plasma total MMP-9 
levels and plasma total cholesterol levels was observed.  
- 36- 
Since it is well known that MMP-9 is produced predominantly by neutrophils and 
monocytes in the blood, white blood cell differential analysis was conducted to determine 
whether the increased plasma MMP-9 levels observed in CD mice were due to changes in 
composition with white blood cells. CD increased the proportion of neutrophils, decreased the 
proportion of lymphocytes and had no effects on monocytes, eosinophils or basophils. The 
treatment of cholestyramine and ezetimibe significantly decreased the proportion of neutrophils 
increased by CD. Moreover, significant correlation between the proportion of neutrophils and 
plasma total cholesterol levels was observed. 
The present study suggests that carbamoyl-PROXYL is a suitable MRI contrast probe 
for visualization of very small disruptions of BBB and the renal dysfunction induced by dietary 
cholesterol in mice. The treatment of cholestyramine and ezetimibe at least partially abolished 
small disruptions of BBB and the renal dysfunction induced by dietary cholesterol. The 
disruptions of BBB and the renal dysfunction were accompanied by the enhancement of plasma 
MMP-9 levels and neutrophils in the blood. 
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